7.37 USD
+0.16 (+2.22%)
7.37 USD
0 (0%)
We assign a fundamental rating of 4 out of 10 to XERS. XERS was compared to 191 industry peers in the Pharmaceuticals industry. XERS has a bad profitability rating. Also its financial health evaluation is rather negative. XERS is growing strongly while it is still valued neutral. This is a good combination!
1. Profitability
1.1 Basic Checks
XERS had negative earnings in the past year.
In the past year XERS had a positive cash flow from operations.
In the past 5 years XERS always reported negative net income.
In the past 5 years XERS always reported negative operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -4.22%, XERS is in the better half of the industry, outperforming 73.44% of the companies in the same industry.
XERS has a Return On Invested Capital of 3.05%. This is amongst the best in the industry. XERS outperforms 80.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.22% | ||
| ROE | N/A | ||
| ROIC | 3.05% |
ROA(3y)-21.25%
ROA(5y)-32.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
XERS's Operating Margin of 3.68% is fine compared to the rest of the industry. XERS outperforms 78.65% of its industry peers.
XERS has a better Gross Margin (84.56%) than 87.50% of its industry peers.
In the last couple of years the Gross Margin of XERS has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 3.68% | ||
| PM (TTM) | N/A | ||
| GM | 84.56% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.81%
GM growth 5Y14.98%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XERS is destroying value.
The number of shares outstanding for XERS has been increased compared to 1 year ago.
The number of shares outstanding for XERS has been increased compared to 5 years ago.
Compared to 1 year ago, XERS has a worse debt to assets ratio.
2.2 Solvency
XERS has an Altman-Z score of 0.55. This is a bad value and indicates that XERS is not financially healthy and even has some risk of bankruptcy.
XERS's Altman-Z score of 0.55 is in line compared to the rest of the industry. XERS outperforms 48.96% of its industry peers.
XERS has a debt to FCF ratio of 22.00. This is a negative value and a sign of low solvency as XERS would need 22.00 years to pay back of all of its debts.
XERS has a better Debt to FCF ratio (22.00) than 75.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 22 | ||
| Altman-Z | 0.55 |
ROIC/WACC0.3
WACC10.08%
2.3 Liquidity
A Current Ratio of 1.93 indicates that XERS should not have too much problems paying its short term obligations.
XERS has a worse Current ratio (1.93) than 62.50% of its industry peers.
A Quick Ratio of 1.35 indicates that XERS should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.35, XERS is doing worse than 68.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.35 |
3. Growth
3.1 Past
XERS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 77.78%, which is quite impressive.
XERS shows a strong growth in Revenue. In the last year, the Revenue has grown by 42.05%.
Measured over the past years, XERS shows a very strong growth in Revenue. The Revenue has been growing by 137.28% on average per year.
EPS 1Y (TTM)77.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)42.05%
Revenue growth 3Y59.98%
Revenue growth 5Y137.28%
Sales Q2Q%37.06%
3.2 Future
XERS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 34.91% yearly.
The Revenue is expected to grow by 23.22% on average over the next years. This is a very strong growth
EPS Next Y88.37%
EPS Next 2Y57.42%
EPS Next 3Y43.51%
EPS Next 5Y34.91%
Revenue Next Year42.95%
Revenue Next 2Y35.2%
Revenue Next 3Y29.39%
Revenue Next 5Y23.22%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for XERS. In the last year negative earnings were reported.
XERS is valuated quite expensively with a Price/Forward Earnings ratio of 40.55.
69.27% of the companies in the same industry are more expensive than XERS, based on the Price/Forward Earnings ratio.
XERS's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 23.46.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 40.55 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, XERS is valued a bit cheaper than the industry average as 76.56% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, XERS is valued a bit cheaper than the industry average as 75.00% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 122.59 | ||
| EV/EBITDA | 62.85 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as XERS's earnings are expected to grow with 43.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y57.42%
EPS Next 3Y43.51%
5. Dividend
5.1 Amount
XERS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
7.37
+0.16 (+2.22%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners59.33%
Inst Owner Change7.96%
Ins Owners2.73%
Ins Owner Change-1.96%
Market Cap1.22B
Revenue(TTM)266.14M
Net Income(TTM)-15.64M
Analysts85
Price Target11.37 (54.27%)
Short Float %10.03%
Short Ratio6.38
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.83%
Min EPS beat(2)-100%
Max EPS beat(2)64.35%
EPS beat(4)2
Avg EPS beat(4)1.9%
Min EPS beat(4)-100%
Max EPS beat(4)64.35%
EPS beat(8)3
Avg EPS beat(8)-2.73%
EPS beat(12)6
Avg EPS beat(12)5.17%
EPS beat(16)9
Avg EPS beat(16)1.29%
Revenue beat(2)1
Avg Revenue beat(2)3.46%
Min Revenue beat(2)-1.7%
Max Revenue beat(2)8.61%
Revenue beat(4)3
Avg Revenue beat(4)2.66%
Min Revenue beat(4)-1.7%
Max Revenue beat(4)8.61%
Revenue beat(8)5
Avg Revenue beat(8)1.52%
Revenue beat(12)9
Avg Revenue beat(12)3.74%
Revenue beat(16)11
Avg Revenue beat(16)2.82%
PT rev (1m)-3.11%
PT rev (3m)23.81%
EPS NQ rev (1m)26.67%
EPS NQ rev (3m)1.33%
EPS NY rev (1m)-73.32%
EPS NY rev (3m)-73.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.14%
Revenue NY rev (1m)0.33%
Revenue NY rev (3m)0.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 40.55 | ||
| P/S | 4.59 | ||
| P/FCF | 122.59 | ||
| P/OCF | 115.82 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 62.85 |
EPS(TTM)-0.1
EYN/A
EPS(NY)0.18
Fwd EY2.47%
FCF(TTM)0.06
FCFY0.82%
OCF(TTM)0.06
OCFY0.86%
SpS1.6
BVpS-0.01
TBVpS-0.69
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.22% | ||
| ROE | N/A | ||
| ROCE | 3.86% | ||
| ROIC | 3.05% | ||
| ROICexc | 4.77% | ||
| ROICexgc | 15.89% | ||
| OM | 3.68% | ||
| PM (TTM) | N/A | ||
| GM | 84.56% | ||
| FCFM | 3.75% |
ROA(3y)-21.25%
ROA(5y)-32.26%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.81%
GM growth 5Y14.98%
F-Score7
Asset Turnover0.72
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 22 | ||
| Debt/EBITDA | 10.21 | ||
| Cap/Depr | 4.99% | ||
| Cap/Sales | 0.22% | ||
| Interest Coverage | 0.37 | ||
| Cash Conversion | 49.13% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.35 | ||
| Altman-Z | 0.55 |
F-Score7
WACC10.08%
ROIC/WACC0.3
Cap/Depr(3y)9.93%
Cap/Depr(5y)22.72%
Cap/Sales(3y)0.76%
Cap/Sales(5y)1.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)77.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y88.37%
EPS Next 2Y57.42%
EPS Next 3Y43.51%
EPS Next 5Y34.91%
Revenue 1Y (TTM)42.05%
Revenue growth 3Y59.98%
Revenue growth 5Y137.28%
Sales Q2Q%37.06%
Revenue Next Year42.95%
Revenue Next 2Y35.2%
Revenue Next 3Y29.39%
Revenue Next 5Y23.22%
EBIT growth 1Y121.7%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year237.04%
EBIT Next 3Y63.41%
EBIT Next 5Y46.27%
FCF growth 1Y113.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y114.95%
OCF growth 3YN/A
OCF growth 5YN/A
XERIS BIOPHARMA HOLDINGS INC / XERS FAQ
Can you provide the ChartMill fundamental rating for XERIS BIOPHARMA HOLDINGS INC?
ChartMill assigns a fundamental rating of 4 / 10 to XERS.
What is the valuation status for XERS stock?
ChartMill assigns a valuation rating of 4 / 10 to XERIS BIOPHARMA HOLDINGS INC (XERS). This can be considered as Fairly Valued.
How profitable is XERIS BIOPHARMA HOLDINGS INC (XERS) stock?
XERIS BIOPHARMA HOLDINGS INC (XERS) has a profitability rating of 3 / 10.
Can you provide the financial health for XERS stock?
The financial health rating of XERIS BIOPHARMA HOLDINGS INC (XERS) is 2 / 10.
Can you provide the expected EPS growth for XERS stock?
The Earnings per Share (EPS) of XERIS BIOPHARMA HOLDINGS INC (XERS) is expected to grow by 88.37% in the next year.